1
TITLE: Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+breast cancer: a plain language summary of the PHERGain study
AUTHORS: Perez Garcia, Jose Manuel; Gebhart, Geraldine; Borrego, Manuel Ruiz; Schmid, Peter; Marme, Frederik; Prat, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Marco; Braga, Sofia; Malfettone, Andrea; Sampayo Cordero, Miguel; Cortes, Javier; Llombart Cussac, Antonio;
PUBLISHED: 2022, SOURCE: FUTURE ONCOLOGY
INDEXED IN: WOS
2
TITLE: Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.
AUTHORS: Javier Cortes; Geraldine Gebhart; Manuel Ruiz Borrego; Agostina Stradella; Begona Bermejo; Santiago Escriva; Lourdes Calvo Martinez; Nuria Ribelles; Noelia Martinez; Cinta Albacar; Aleix Prat; Florence Dalenc; Kerrou Khaldoun; Peter Schmid; Marco Colleoni; Frederik Marme; Noemia Afonso; Miguel Sampayo Cordero; Jose Manuel Perez Garcia; Antonio Llombart Cussac;
PUBLISHED: 2020, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 38, ISSUE: 15
INDEXED IN: WOS
3
TITLE: Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis
AUTHORS: Glen Kristiansen; Eda Machado; Niko Bretz; Christian Rupp; Klaus Juergen Winzer; Anne Kathleen Koenig; Gerhard Moldenhauer; Frederik Marme; Julia Costa ; Peter Altevogt;
PUBLISHED: 2010, SOURCE: LABORATORY INVESTIGATION, VOLUME: 90, ISSUE: 7
INDEXED IN: Scopus WOS CrossRef